Correlation Between Tempest Therapeutics and Moleculin Biotech

Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and Moleculin Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and Moleculin Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tempest Therapeutics and Moleculin Biotech, you can compare the effects of market volatilities on Tempest Therapeutics and Moleculin Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of Moleculin Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and Moleculin Biotech.

Diversification Opportunities for Tempest Therapeutics and Moleculin Biotech

0.23

Correlation Coefficient

Tempest Therapeutics  Moleculin Biotech

Modest diversification

The 3 months correlation between Tempest and Moleculin is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and Moleculin Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moleculin Biotech and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with Moleculin Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moleculin Biotech has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and Moleculin Biotech go up and down completely randomly.

Pair Corralation between Tempest Therapeutics and Moleculin Biotech

Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the Moleculin Biotech. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 9.31 times less risky than Moleculin Biotech. The stock trades about -0.01 of its potential returns per unit of risk. The Moleculin Biotech is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  165.00  in Moleculin Biotech on December 27, 2024 and sell it today you would lose (58.00) from holding Moleculin Biotech or give up 35.15% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Tempest Therapeutics  vs.  Moleculin Biotech

Tempest Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Tempest Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Moleculin Biotech

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Moleculin Biotech are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Moleculin Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Tempest Therapeutics and Moleculin Biotech

The main advantage of trading using opposite Tempest Therapeutics and Moleculin Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, Moleculin Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will offset losses from the drop in Moleculin Biotech's long position.

The idea behind Tempest Therapeutics and Moleculin Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.